News >

Immunotherapy Shows Early Promise in Advanced Sarcomas

Sandra Kear
Published: Monday, Dec 07, 2015

Arun Singh, MD

Arun Singh, MD

Early research has shown promise for adoptive cellular therapy with autologous lymphocytes genetically modified to express an NY-ESO-1-specific T-cell receptor and dendritic cell vaccination in combination with ipilimumab (Yervoy) in patients with advanced sarcomas. The data were presented at the 2015 Connective Tissue Oncology Society (CTOS) Annual Meeting.

Singh A, Chmielowski B, Berent-Maoz B, et al. Adoptive cellular therapy with autologous lymphocytes genetically modified to express an NY-ESO-1 Specific T-cell receptor and dendritic cell vaccination with or without ipilimumab in patients with advanced sarcomas and melanoma. Presented at: The 2015 Annual Meeting of the Connective Tissue Oncology Society; November 5, 2015; Salt Lake City, UT. Abstract 010.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x